Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms

被引:1
|
作者
Zhang, Yuhui [1 ]
Han, Yingdi [1 ]
Teng, Guangshuai [1 ]
Du, Chenxiao [1 ]
Gao, Shan [1 ]
Yuan, Weiping [2 ]
Zhang, Lei [2 ]
Bai, Jie [1 ]
机构
[1] Second Hosp Tianjin Med Univ, Dept Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Natl Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China
来源
CANCER MEDICINE | 2023年 / 12卷 / 08期
基金
中国国家自然科学基金;
关键词
clinical characteristics; myeloproliferative neoplasms; risk factors; secondary cancer; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; ADULT PATIENTS; SOLID TUMORS; CANCER; TRANSFORMATION; SURVIVAL;
D O I
10.1002/cam4.5666
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectiveThe clinical characteristics and survival of patients with myeloproliferative neoplasms (MPNs) with secondary cancer were analyzed to explore the possible risk factors for secondary cancer in MPN patients. MethodsThe clinical characteristics of 1060 Chinese patients with MPN were retrospectively analyzed. The Kaplan-Meier method was used to analyze the survival. The Cox multivariate regression model was used to analyze the risk factors for developing secondary cancer in patients with MPNs. ResultsThe 1060 patients with MPN had a median follow-up of 10 years (range 1-50) and a median age of 55 years (range 21-86), and 497 (45.2%) were male. The proportion of PV, ET, and PMF was 52.2%, 33.5%, and 14.3%, respectively. About 28.1% (298/1060) of 1060 MPN patients died. The median survival times of the PV, ET, and PMF groups were 20, 24, and 12 years, respectively (p < 0.0001). In age- and sex-matched healthy Chinese patients, the standardized incidence ratio (SIR) value of developing secondary cancer in MPN patients was 6.41 (95% CI: 4.90-9.48). The median survival time was 14 years in the MPN with secondary cancer group. The Cox multivariate analysis showed that age >= 65 years (p < 0.0001, HR = 5.027, 95% CI [2.823, 8.952]), MF-1 (p = 0.001, HR = 2.887, 95% CI [1.503, 5.545]) were risk factors for developing secondary cancer. ConclusionsThe survival of MPN patients with secondary cancer was significantly worse than that of patients without secondary cancer. Compared with normal subjects, MPN patients had a 6.41-fold increased risk of developing secondary cancer, and age >= 65 years and MF-1 were risk factors for developing secondary cancer in MPN patients.
引用
收藏
页码:9236 / 9246
页数:11
相关论文
共 50 条
  • [41] Risk of second primary malignancies among patients with carcinoid of the lung
    Buikhuisen, Wieneke A.
    Steinbusch, Laurie C.
    Kodach, Liudmila L.
    Tesselaar, Margot E. T.
    Damhuis, Ronald A. M.
    LUNG CANCER, 2021, 151 : 5 - 7
  • [42] Incidence, Risk Factors and Outcomes of Pulmonary Embolism in Philadelphia Negative Myeloproliferative Neoplasms: A Population Based Study
    Gonzalez-Mosquera, Luis F.
    Moscoso, Bernard
    Cardenas-Maldonado, Diana
    Tobar, Pool
    Podrumar, Alida I.
    Cuenca, John A.
    BLOOD, 2021, 138 : 3654 - +
  • [43] Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis
    Hu, Tulan
    Wang, Wei
    He, Chiyi
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [44] Incidence and associated factors of developing second pelvic malignant neoplasms among prostate cancer patients treated with radiotherapy
    Wang, Youbiao
    Chen, Ru
    Deng, Xinxi
    Jiang, Xinghua
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [45] Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients
    Jindamai, Yanika
    Rattarittamrong, Ekarat
    Phrommintikul, Arintaya
    Yongsmith, Lalita
    Piriyakhuntorn, Pokpong
    Rattanathammethee, Thanawat
    Hantrakool, Sasinee
    Chai-Adisaksopha, Chatree
    Tantiworawit, Adisak
    Norasetthada, Lalita
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (05) : 631 - 639
  • [46] Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms
    Wen, Shirong
    Zhang, Wenxiao
    Fei, Yiping
    Guan, Ke
    Song, Peng
    Zhao, Hui
    Ye, Xiangmei
    Pan, Yujun
    JOURNAL OF CLINICAL NEUROSCIENCE, 2024, 125 : 159 - 166
  • [47] Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients
    Yanika Jindamai
    Ekarat Rattarittamrong
    Arintaya Phrommintikul
    Lalita Yongsmith
    Pokpong Piriyakhuntorn
    Thanawat Rattanathammethee
    Sasinee Hantrakool
    Chatree Chai-Adisaksopha
    Adisak Tantiworawit
    Lalita Norasetthada
    International Journal of Hematology, 2020, 112 : 631 - 639
  • [48] Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
    V De Stefano
    A M Vannucchi
    M Ruggeri
    F Cervantes
    A Alvarez-Larrán
    A Iurlo
    M L Randi
    L Pieri
    E Rossi
    P Guglielmelli
    S Betti
    E Elli
    M C Finazzi
    G Finazzi
    E Zetterberg
    N Vianelli
    G Gaidano
    I Nichele
    D Cattaneo
    M Palova
    M H Ellis
    E Cacciola
    A Tieghi
    J C Hernandez-Boluda
    E Pungolino
    G Specchia
    D Rapezzi
    A Forcina
    C Musolino
    A Carobbio
    M Griesshammer
    T Barbui
    Blood Cancer Journal, 2016, 6 : e493 - e493
  • [49] Treatment-Related Infections and Risk Factors in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib
    King, Amber C.
    Hsu, Meier
    Mauro, Michael J.
    Rampal, Raajit K.
    BLOOD, 2016, 128 (22)
  • [50] Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
    De Stefano, V.
    Vannucchi, A. M.
    Ruggeri, M.
    Cervantes, F.
    Alvarez-Larran, A.
    Iurlo, A.
    Randi, M. L.
    Pieri, L.
    Rossi, E.
    Guglielmelli, P.
    Betti, S.
    Elli, E.
    Finazzi, M. C.
    Finazzi, G.
    Zetterberg, E.
    Vianelli, N.
    Gaidano, G.
    Nichele, I.
    Cattaneo, D.
    Palova, M.
    Ellis, M. H.
    Cacciola, E.
    Tieghi, A.
    Hernandez-Boluda, J. C.
    Pungolino, E.
    Specchia, G.
    Rapezzi, D.
    Forcina, A.
    Musolino, C.
    Carobbio, A.
    Griesshammer, M.
    Barbui, T.
    BLOOD CANCER JOURNAL, 2016, 6 : e493 - e493